Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme

被引:59
作者
Barnes, T. R. E. [1 ]
Paton, C. [1 ]
Hancock, E. [2 ]
Cavanagh, M. -R. [2 ]
Taylor, D. [3 ]
Lelliott, P. [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Med Psychol, London W6 8RP, England
[2] Royal Coll Psychiatrists, Ctr Qual Improvement, London, England
[3] S London & Maudsley NHS Fdn Trust, London, England
关键词
metabolic syndrome; antipsychotics; screening;
D O I
10.1111/j.1600-0447.2008.01203.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. Method: Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later. Results: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. Conclusion: The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams.
引用
收藏
页码:26 / 33
页数:8
相关论文
共 39 条
[1]   Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
DIABETIC MEDICINE, 2006, 23 (05) :469-480
[3]   A UK audit of screening for the metabolic side effects of antipsychotics in community patients [J].
Barnes, Thomas R. E. ;
Paton, Carol ;
Cavanagh, Mary-Rose ;
Hancock, Elizabeth ;
Taylor, David M. .
SCHIZOPHRENIA BULLETIN, 2007, 33 (06) :1397-1403
[4]  
BARNES TRE, 2003, GALLIARD HEALTHCARE, P7
[5]   Hypertension and ethnic group [J].
Brown, MJ .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7545) :833-836B
[6]   The unhealthy lifestyle of people with schizophrenia [J].
Brown, S ;
Birtwistle, J ;
Roe, L ;
Thompson, C .
PSYCHOLOGICAL MEDICINE, 1999, 29 (03) :697-701
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome [J].
Cohn, Tony ;
Prud'homme, Denis ;
Streiner, David ;
Kameh, Homa ;
Remington, Gary .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2004, 49 (11) :753-760
[9]   Does antipsychotic polypharmacy increase the risk for metabolic syndrome? [J].
Correll, Christoph U. ;
Frederickson, Anne M. ;
Kane, John M. ;
Manu, Peter .
SCHIZOPHRENIA RESEARCH, 2007, 89 (1-3) :91-100
[10]   Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication [J].
De Hert, MA ;
van Winkel, R ;
Van Eyck, D ;
Hanssens, L ;
Wampers, M ;
Scheen, A ;
Peuskens, J .
SCHIZOPHRENIA RESEARCH, 2006, 83 (01) :87-93